Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
Open Access
- 2 March 2005
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (5), 602-604
- https://doi.org/10.1111/j.1365-2125.2005.02354.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Pharmacogenetics, 2004
- Pharmacogenomics of the OATP and OAT FamiliesPharmacogenomics, 2004
- Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClinical Pharmacology & Therapeutics, 2004
- Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in HumanJournal of Pharmacology and Experimental Therapeutics, 2003
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- Polymorphisms in OATP-CPublished by Elsevier BV ,2001
- Identification of functionally variant MDR1 alleles among European Americans and African AmericansClinical Pharmacology & Therapeutics, 2001
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 2000
- Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) FamilyBiochemical and Biophysical Research Communications, 2000
- Clinical Pharmacology of New Histamiine H1 Receptor AntagonistsClinical Pharmacokinetics, 1999